Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

[1]  S. Yamagishi,et al.  Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. , 2011, Pharmacological research.

[2]  W. L. Jin,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. , 2011, Biochemical and biophysical research communications.

[3]  S. Miyamoto,et al.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.

[4]  M. Shichiri,et al.  Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. , 2010, Atherosclerosis.

[5]  R. D. de Boer,et al.  Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[6]  S. N. Murthy,et al.  The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats , 2010, Diabetes & vascular disease research.

[7]  Yutaka Seino,et al.  Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. , 2010, Endocrine journal.

[8]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[9]  Youichi Kobayashi,et al.  Preventive Effects of Heregulin-&bgr;1 on Macrophage Foam Cell Formation and Atherosclerosis , 2009, Circulation research.

[10]  S. Shioda,et al.  Leptin modulates ACAT1 expression and cholesterol efflux from human macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[11]  M. Nagasawa,et al.  Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. , 2009, Atherosclerosis.

[12]  Alberto Smith,et al.  The monocyte/macrophage as a therapeutic target in atherosclerosis. , 2009, Current opinion in pharmacology.

[13]  A. Dear,et al.  A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. , 2009, The Journal of endocrinology.

[14]  J. Egan,et al.  The Role of Incretins in Glucose Homeostasis and Diabetes Treatment , 2008, Pharmacological Reviews.

[15]  N. Irwin,et al.  (Pro3)GIP[mPEG]: novel, long‐acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity‐diabetes (diabesity) therapy , 2008, British journal of pharmacology.

[16]  M. Adachi,et al.  Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice , 2008, Journal of hypertension.

[17]  M. Shichiri,et al.  Impact of Salusin-α and -β on Human Macrophage Foam Cell Formation and Coronary Atherosclerosis , 2008, Circulation.

[18]  I. Shimomura,et al.  Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes , 2007, Diabetologia.

[19]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[20]  M. Adachi,et al.  Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages , 2005, Hypertension.

[21]  Tanya Hansotia,et al.  GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice , 2005, Regulatory Peptides.

[22]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[23]  A. Gotto,et al.  Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. , 2000, Journal of lipid research.

[24]  K. Botham.  Cyclic AMP and the regulation of cholesterol metabolism. , 1992, Biochemical Society transactions.

[25]  F. Palmieri,et al.  Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells. , 1989, Advances in experimental medicine and biology.